Nearing All-Time Highs
Nearing All-Time Highs
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, Argo,
Recent bear target Pantheon Resources (PANR), the AIM-quoted oil company, provided an operational update on the Alkaid #2 well.
OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO),— an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, Bushveld,
OKYO Pharma (OKYO), an ophthalmology-focused bio-pharmaceutical company, announced that it has received clearance of its Investigational New Drug (IND) application from the FDA to initiate a Phase 2, first-in-human, clinical
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
We perhaps found out today why shares of Oriole Resources (ORR) have been such a firm market of late. The AIM-quoted gold exploration company reported that its partner IAMGOLD Corporation
London and New York, NY., 21 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to
LifeSafe (LIFS), a fire safety technology business, provides a trading update for the eleven month period ended 30 November 2022. The company reported that sales growth through the Group’s consumer
LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease